The existing dogma dictates that EGFR-mutant and MET-amplified lung cancers codepend on the concurrent activation of both EGFR and a MET kinases for survival, making them unresponsive to single-agent TKI treatment against either receptor. Here, MET is linked to lung carcinoma.